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Abstract
Hepatoblastoma is the most frequently diagnosed liver tumor of childhood, and children with advanced, metastatic
or relapsed disease have a disease-free survival rate under 50%. Focal adhesion kinase (FAK) is a nonreceptor
tyrosine kinase that is important in many facets of tumor development and progression. FAK has been found in
other pediatric solid tumors and in adult hepatocellular carcinoma, leading us to hypothesize that FAK would be
present in hepatoblastoma and would impact its cellular survival. In the current study, we showed that FAK was
present and phosphorylated in human hepatoblastoma tumor specimens. We also examined the effects of FAK
inhibition upon hepatoblastoma cells using a number of parallel approaches to block FAK including RNAi and small
molecule FAK inhibitors. FAK inhibition resulted in decreased cellular survival, invasion, andmigration and increased
apoptosis. Further, small molecule inhibition of FAK led to decreased tumor growth in a nude mouse xenograft
model of hepatoblastoma. The findings from this study will help to further our understanding of the regulation of
hepatoblastoma tumorigenesis and may provide desperately needed novel therapeutic strategies and targets for
aggressive, recurrent, or metastatic hepatoblastomas.
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Introduction
Hepatoblastoma is the most frequently diagnosed malignant liver
tumor in children. These tumors originate from immature liver precur-
sor cells and likely result from a developmental disturbance causing
aberrant cellular proliferation [1]. Although chemotherapy in conjunc-
tion with radical surgical resection has improved the prognosis for
patients with hepatoblastoma [2], disease-free survival rates remain less
than 50% for patients with advanced, metastatic or relapsed disease.
For this reason, novel therapeutic options are needed for the treatment
of these children.
Focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase
that has been found to regulate cellular signaling pathways for multiple
functions, such as adhesion, proliferation, and survival. Integrins bind
to the β subunits of FAK, leading to FAK phosphorylation and the
binding of Src family kinases, resulting in a FAK-Src complex, which
promotes cellular migration and growth [3]. FAK is also activated by
autophosphorylation at the tyrosine 397 (Y397) residue, which results
in downstream survival signaling through activation of phosphatidyl-
inositol 3′-kinase (PI3K) and increased expression of inhibitor of
apoptosis proteins [4]. FAK has been shown to be overexpressed and
to correlate with tumor aggressiveness in a number of human tumors
including breast and colon cancer [5] and the pediatric solid tumor
neuroblastoma [6]. Abrogation of FAK with multiple modalities in-
cluding small interfering RNA (siRNA) [7], AdFAK-CD [8,9], and
small molecule inhibitors [10–12] has been shown to decrease cellular
migration and survival in multiple tumor types.
Investigators have found FAK expression in hepatocellular carcinoma
tumor specimens and cell lines, and FAK augmented the invasive and
metastatic potential in these tumors [13]. Knowing the importance of
FAK in other tumor types and with the data from the hepatocellular
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carcinoma studies, we hypothesized that FAK would be present in
hepatoblastoma and would impact cellular survival in this liver tumor.
To confirm our hypotheses, we used immunohistochemistry to illus-
trate the presence of FAK in human hepatoblastoma specimens and
immunoblot analysis to determine FAK expression in the HuH6
hepatoblastoma cell line. Furthermore, we illustrated that FAK inhibi-
tion with siRNA and small molecule inhibitors resulted in decreased
cellular invasion and viability in vitro and decreased hepatoblastoma
xenograft growth in vivo. These studies demonstrated that targeting
FAK may present a novel treatment strategy for hepatoblastoma.
Materials and Methods
Tumor Specimens and Cell Line
Formalin-fixed, paraffin-embedded hepatoblastoma specimens were
obtained from our institution after Institutional Review Board approval
(X111123007). The Institutional Review Board waived the need for
informed consent since the specimens were previously obtained for
the purposes of diagnosis and treatment. The hepatoblastoma cell
line, HuH6, was kindly provided by Dr Thomas Pietschmann
[14]. The HuH6 cell line was maintained at 37°C and 5% CO2 in
Dulbecco’smodified Eagle’smediumwith 10%FBS, 2mML-glutamine,
and 1 μg/ml penicillin/streptomycin. The mouse endothelial fibroblasts
with (MEFFAK+/+) and without (MEFFAK−/−) FAK expression were a
kind gift from Dr Elena Kurenova. These cell lines were maintained
in Dulbecco’s modified Eagle’s medium with 10% FBS, 2 mM
L-glutamine, and 1 μg/ml penicillin/streptomycin at 37°C and 5% CO2.
Antibodies and Reagents
Antibodies used for Western blot analysis were given as follows:
Mouse monoclonal anti-FAK (4.47) and rabbit polyclonal anti–
phospho-FAK (Y397) antibodies were obtained from EMDMillipore
(Billerica, MA; 05-537) and Invitrogen Corp (Carlsbad, CA; 4624G),
respectively. Antibody for cleaved poly (ADP-ribose) polymerase
(PARP) was from Cell Signaling Technology, Inc (Danvers, MA;
9542s, rabbit polyclonal). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) antibodywas fromFitzgerald Industries International (Acton,
MA; 10R-1178) and β-actin antibody was from Santa Cruz Biotech-
nology, Inc (Santa Cruz, CA).
siRNA was obtained from Qiagen Inc (Valencia, CA) and used as
previously described [15]. Briefly, cells were plated and allowed to attach
for 24 hours and were then transfected with Hyperfect (Qiagen Inc)
alone, Hyperfect (Qiagen Inc) plus control siRNA (AllStars Negative
Control siRNA; Qiagen Inc), or Hyperfect (Qiagen Inc) plus FAK
siRNA [Hs_PTK2_10 FlexiTube siRNA (NM_005607,NM_153831);
Qiagen Inc] according to the manufacturer’s protocol. Cells were incu-
bated for 24 to 72 hours after transfection and then used for experiments.
The small molecules PF-573,228 (PF) and 1,2,4,5-benzenetetraamine
tetrahydrochloride (C6H10N4·4ClH; Y15) were obtained from Santa
Cruz Biotechnology, Inc.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tumor blocks for the human
specimens or murine xenografts were cut in 8-μm sections. The slides
were baked for 1 hour at 70°C, deparaffinized, rehydrated, and
steamed. The sections were then quenched with 3% hydrogen per-
oxide and blocked with phosphate-buffered saline–blocking buffer.
The primary antibodies, anti-FAK 4.47 (1:100, mouse monoclonal,
05-537; EMD Millipore) and anti–phospho-FAK (Y397) (1:200,
rabbit polyclonal, 4624G; Invitrogen Corp), were added and incubated
overnight at 4°C. After washing with phosphate-buffered saline, the
secondary antibodies were added at 1:250 dilution (Jackson Immuno-
Research Laboratories, Inc, West Grove, PA) for 1 hour at 22°C.
The staining reaction was developed with VECTASTAIN Elite ABC
Kit (PK-6100; Vector Laboratories, Burlingame, CA), TSA (Biotin
Tyramide Reagent, 1:400; PerkinElmer, Inc, Waltham, MA), and
DAB (Metal Enhanced DAB Substrate; Thermo Fisher Scientific,
Rockford, IL). Slides were counterstained with hematoxylin. Negative
controls [mouse IgG (1 μg/ml; Invitrogen Corp) or rabbit IgG (1 μg/ml;
EMD Millipore)] were included with each run.
Immunohistochemistry Scoring
A single board-certified pathologist (E.M.M.), blinded to the speci-
mens, reviewed each human tissue section for FAK and phosphor-
FAK and assigned a stain score. Scoring was based on a system that
has been used previously [6]. The slides were examined and the stain-
ing evaluated by measuring the intensity of stain (0, none; 1, weak;
2, moderate; 3, strong; 4, extremely strong) and the percentage of pos-
itive cells (0–100). A stain score was calculated based on the percent
positive cells and the amount of staining. For instance, if the specimen
showed moderate staining (2) in 70% of the cells, the calculated stain
score would be 2 × 70 = 140.
Immunoblot Analysis
Western blots were performed as previously described [12].
Briefly, cells or homogenized xenograft specimens were lysed on ice for
30 minutes in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1%Triton X-100, 0.5%NaDOC, 0.1% sodium dodecyl sulfate
(SDS), 5 mM EDTA, 50 mMNaF, 1 mMNaVO3, 10% glycerol, and
protease inhibitors: 10 μg/ml leupeptin, 10 μg/ml phenylmethylsulfonyl
fluoride (PMSF), and 1 μg/ml aprotinin. The lysates were cleared by
centrifugation at 10,000 rpm for 30 minutes at 4°C. Protein concentra-
tions were determined using a Bio-Rad kit (Bio-Rad, Hercules, CA) and
proteins were separated by electrophoresis on SDS–polyacrylamide gel
electrophoresis gels. Antibodies were used according to the manufac-
turer’s recommended conditions. Molecular weight markers (Precision
Plus Protein Kaleidoscope Standards; Bio-Rad)were used to confirm the
expected size of the target proteins. Immunoblots were developed with
chemiluminescence (Amersham ECL Western Blotting Detection
Reagents; GE Healthcare Life Sciences, Piscataway, NJ). Blots were
stripped with stripping solution (Bio-Rad) at 37°C for 15 minutes
and then reprobed with selected antibodies. Immunoblot analysis with
antibody to β-actin or GAPDH provided an internal control for equal
protein loading.
Cell Viability Assays
Equal numbers of cells were plated and allowed to attach for 24 hours.
Cells were treated with RNAi inhibition, PF, or Y15, and cell viability
was measured using alamarBlue assay. In brief, 1.5 × 103 cells per well
were plated onto 96-well culture plates and allowed to attach. Following
treatment, 10 μl of alamarBlue dye was added to 200 μl of cell medium.
After 4 to 6 hours, the absorbance at 595 nm was measured using a
kineticmicroplate reader (BioTekGen5; BioTek Instruments,Winooski,
VT). Cell viability was also studied using trypan blue exclusion and cell
counting with a hemacytometer. Viability was reported as fold change.
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Cellular Invasion Assay
Twelve-well culture plates with 8-μm micropore inserts were used
for cell invasion assays. The top side of the insert was coated with
Matrigel (BD Biosciences, San Jose, CA; 1 mg/ml, 50 μl for 4 hours
at 37°C). Cells were treated with PF or Y15 and 3 × 105 cells were
placed into the upper well, cultured for 48 hours and allowed to invade
into the Matrigel layer. The cells on the inserts were fixed with 3%
paraformaldehyde, stained with crystal violet, and counted with a light
microscope. Invasion was reported as fold change in number of cells
invading into the Matrigel.
Migration Assay
Similar to invasion, 12-well culture plates with 8-μm micropore
inserts were used for cell migration assays, with the bottom side of the
insert coated with collagen (MP Biomedicals, Thermo Fisher Scientific;
1 mg/ml, 50 μl for 4 hours at 37°C). Cells were treated with PF or Y15
and 3 × 105 cells were placed into the upper well, cultured for 24 hours,
and allowed to invade through the transwell plate. The cells on the
inserts were fixedwith 3%paraformaldehyde, stained with crystal violet,
and counted with a light microscope. Migration was reported as fold
change in number of cells migrating through the transwell plate.
Attachment-Independent Growth Assay
Attachment-independent growth was determined by soft agar assay.
A base layer of complete culture media in 1% noble agar was established
in 60-mm culture dishes. HuH6 cells were plated at 1 × 104 cells per
dish in the top layer composed of the same culture media and agar
mixture. Dishes were treated with graduated concentrations of PF or
Y15. After incubation for 12 days, colonies were imaged and quantified
using the Gel Dock Imager (Bio-Rad) and Quantity One Software
(Bio-Rad), respectively. Colony counts were reported as means ± SEM.
Apoptosis Assays
Apoptosis was detected bymeasuring activation of caspase-3 (Caspase-3/
CPP32 Colorimetric Protease Assay; Invitrogen Corp) according to the
manufacturer’s instructions. Briefly, cells were treated with PF or Y15
and plated onto 96-well plates. After 48 hours, cells were lifted and
lysed. Cell lysates were incubated in reaction buffer containing DTT
and DEVD-pNA substrate and read at 405 nm using a kinetic micro-
plate reader (BioTek Gen5). Caspase-3 activation was reported as fold
change in activation. Apoptosis was also documented by immunoblot
analysis for PARP cleavage. Cells were treated with PF or Y15; lysates
were collected, and immunoblot analysis for cleaved PARP was per-
formed. Bands were detected by chemiluminescence and β-actin served
as an internal control.
Tumor Growth In Vivo
Six-week-old, female, athymic nude mice were used (Harlan Lab-
oratories, Inc, Chicago, IL). The mice were maintained in an specific
pathogen free (SPF) animal facility with standard 12-hour light/dark
cycles and allowed chow and water ad libitum. All experiments were
performed after obtaining protocol approval from the Animal Care
and Use Committee (110209355) and in compliance with the insti-
tutional, national, and National Institutes of Health animal use guide-
lines. Human hepatoblastoma cells, HuH6 (2 × 106 cells) in Matrigel
(BD Biosciences), were injected subcutaneously into the right flank.
Figure 1. FAK in hepatoblastoma human specimens and HuH6 cell line. Immunohistochemistry staining with antibodies specific for FAK
and phospho-FAK was performed on 28 formalin-fixed, paraffin-embedded human hepatoblastoma specimens. (A) Representative
photomicrographs show staining of the hepatoblastoma cells for FAK and phospho-FAK. Negative controls (lower white inserts, left
panels) were included with each run. FAK staining was detected in 23 of 28 specimens (top panels) and was phosphorylated in 71%
(bottom panels). (B) Immunoblot analysis for Y397 FAK and total FAK was performed on HuH6 hepatoblastoma cell lysates. There was
FAK present and it was phosphorylated at the Y397 site. Lysates from mouse endothelial fibroblasts with (MEFFAK+/+) and without
(MEFFAK−/−) FAK served as positive and negative controls, respectively.
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Animals were treated twice daily with intraperitoneal injections of con-
trol vehicle (normal saline, N = 9) or Y15 (30 mg/kg/day, N = 10).
Previous experiments with various doses and dosing schedules of the
compound proved this dosage to be well tolerated [10–12]. Tumors
were measured twice weekly with a caliper and tumor volume in
mm3 was calculated using the standard formula [(width)2 × length]/2,
where width was the smaller diameter. When control tumors reached
the volume allowed by the Institutional Animal Care andUseCommittee
(IACUC) protocol (after 3 weeks of treatment), the animals were killed
with CO2 and bilateral thoracotomy, and the tumors were harvested.
Data Analysis
Experiments were repeated at least in triplicate, and data are reported
as means ± SEM. An analysis of variance or Student’s t test was used
as appropriate to compare data between groups. Statistical significance
was determined at the P < .05 level.
Results
FAK Was Present in Hepatoblastoma Human Specimens
and Cell Line
Immunohistochemistrywas performed on 28 humanhepatoblastoma
specimens. FAK staining was detected in 23 of 28 specimens and
was phosphorylated in 19 of the 28 specimens (71%; Figure 1A). The
stain scores for FAK ranged from 0 to 140, with a mean FAK stain score
of 33.7 ± 8.1. Immunoblot analysis revealed that the HuH6 cell line
expressed FAK and that FAK was phosphorylated at the Y397 site
(Figure 1B). Mouse endothelial fibroblasts with (MEFFAK+/+) and with-
out (MEFFAK−/−) FAK were used for comparison (Figure 1B).
FAK Inhibition with RNA Silencing Led to
Decreased Hepatoblastoma Viability
Since FAK regulates cell survival, we investigated the effects of FAK
silencing with siRNA on hepatoblastoma viability. Treatment with FAK
siRNA (20 and 40 nM) for 24 hours successfully inhibited FAK protein
expression inHuH6 cells (Figure 2A).HuH6 cell viability wasmeasured
with trypan blue after abrogation of FAK with siRNA for 24 hours. Cell
death increased significantly after treatment with FAK siRNA at 20 nM
(Figure 2B) and more than two-fold after treatment with 40 nM FAK
siRNA compared to control (Figure 2B). Control siRNA did not alter
FAK expression (Figure 2A) or significantly increase HuH6 cell death
(Figure 2B). We concluded that silencing FAK with siRNA signifi-
cantly decreased viability in HuH6 cells.
PF Inhibited Phosphorylation of FAK inHumanHepatoblastoma
Cells and Led to Decreased Viability, Invasion, and
Migration and Increased Apoptosis
We wished to further examine the effects of FAK inhibition using a
small molecule FAK inhibitor. PF has been shown to decrease FAK
phosphorylation [17]. HuH6 cells were treated with increasing con-
centrations of PF for 48 hours, and immunoblot analysis was used to
detect FAK expression and phosphorylation. PF treatment of theHuH6
cells led to decreased phosphorylation of FAK Y397 (Figure 3A). Next,
we wished to determine if PF-induced loss of FAK phosphorylation
resulted in decreased cell survival. AlamarBlue assays were used to eval-
uate cell viability after treatment with PF. After 48 hours of PF treat-
ment, there was a statistically significant decrease in viability (Figure 3B).
At a PF concentration of 5 μM, cell viability decreased to 25 ± 3.0%
compared to control (P ≤ .01; Figure 3B). The calculated lethal con-
centration 50 for PF in the HuH6 cells was 4 μM.
In addition to being important in cell survival, FAK also plays a
role in cellular invasion and migration [16]. Since PF treatment re-
sulted in a loss of FAK phosphorylation, we decided to investigate
the effects of PF on HuH6 invasion and migration. Cells were treated
with PF for 48 hours and transwell invasion assays were used. Treat-
ment with PF decreased cellular invasion to 72 ± 10.0% of control at
2.5 μM concentration (Figure 3C ). For migration, cells were treated
with PF and their ability to migrate through a transwell plate was mea-
sured. Treatment with PF resulted in a decrease in cellular migration
that reached significance at 2.5 μM concentration (Figure 3D). Finally,
the impact of FAK inhibition on attachment-independent growth
through the formation of colonies in soft agar was studied. HuH6 cells
were treated with PF, grown in soft agar for 12 days, and colonies were
quantified. Colony count was significantly decreased with PF treatment
Figure 2. FAK inhibition with siRNA in HuH6 human hepatoblastoma
cells. (A) TheHuH6cellswere treatedwith FAKsiRNAor control siRNA.
Immunoblot analysis was used to confirm FAK protein knockdown.
After treatment with FAK siRNA for 24 hours, there was a decrease
in FAK protein expression. Densitometry was used to quantitate FAK
inhibition, with FAK expressed relative to the β-actin bands (bottom
graph). (B) HuH6 cells were treated with FAK siRNA at 20 and 40 nM
for 24 hours and cell viability was measured using trypan blue assay.
There was a significant increase in the number of nonviable cells after
siRNA treatment. The control siRNA had no effect on cellular viability.
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compared to untreated cells (Figure 3E). These experiments illustrated
that inhibition of FAK phosphorylation in HuH6 hepatoblastoma cells
results in diminished cell viability, invasion, migration and attachment-
independent growth.
Finally, since PF resulted in decreased cell survival, we examined the
effects of PF on apoptosis in the HuH6 hepatoblastoma cell line.
Apoptosis wasmeasured with both a caspase activation kit and immuno-
blot analysis for PARP cleavage products. Caspase-3 was significantly
activated after treatment with 10 μM PF for 48 hours (Figure 4A). To
further document that the cells were undergoing apoptosis, HuH6 cells
were treated with PF and lysates were examined with immunoblot anal-
ysis for PARP cleavage products. Treatment with PF led to an increase in
cleaved PARP (Figure 4B), indicating that apoptosis was occurring in the
HuH6 cells.
Y15 Inhibited FAK Phosphorylation in Human Hepatoblastoma
Cells and Resulted in Decreased Cell Survival, Invasion,
Migration, and Increased Apoptosis
We wished to move forward with animal studies, but PF was not
formulated for in vivo studies [17]. Therefore, we chose to use Y15,
Figure 3. PF inhibition of FAK phosphorylation in human hepatoblastoma cells. (A) The HuH6 hepatoblastoma cell line was treated for
48 hours with increasing concentrations of PF and cell lysates were harvested. Immunoblot analysis was used to examine FAK Y397
phosphorylation and total FAK in the lysates. Densitometry was performed, and FAK phosphorylation was reported as a ratio between
the density of the Y397 phospho-FAK band to the density of the total FAK band. Increasing concentrations of PF resulted in decreased
FAK phosphorylation. (B) AlamarBlue assay was used to measure cell viability. HuH6 hepatoblastoma cells were treated with PF at
increasing concentrations for 48 hours. Cellular viability was decreased with a PF concentration of 2.5 μM but did not reach statistical
significance until the 5 μM concentration. (C) HuH6 cells were treated with increasing concentrations of PF and allowed to invade
through a Matrigel-coated micropore insert. Invasion was reported as fold change. Cellular invasion was significantly decreased with
PF beginning at the 2.5 μM concentration. (D) HuH6 cells were treated with increasing concentrations of PF and allowed to migrate
through a micropore insert. Migration was reported as fold change in number of cells migrating through the membrane. Cellular migra-
tion was significantly decreased with PF treatment, and as seen with invasion, the effects of PF upon migration were significant at a
concentration of 2.5 μM. (E) Attachment-independent growth in soft agar was used to further characterize tumor invasiveness. HuH6
cells were treated with increasing concentrations of PF, grown in soft agar for 12 days, and colonies were quantified. Colony count was
significantly decreased with PF treatment compared to untreated cells.
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one of only a few small molecule FAK inhibitors that may be used in
animals [10–12]. Y15 has been previously described and was designed
to inhibit Y397 phosphorylation of FAK [10]. We established with
immunoblot analysis that treatment with Y15 led to a decline in FAK
phosphorylation in the HuH6 hepatoblastoma cells (Figure 5A). We
next investigated whether this loss of Y397 FAK phosphorylation by
Y15 would affect cell survival. Viability was detected with alamarBlue
assay. Treatment with Y15 resulted in a decrease in hepatoblastoma
cellular viability that was significant at a concentration of 5 μM (100 vs
56.1 ± 3.0%, control vs Y15; P ≤ 0.01; Figure 5B).
Similar to the PF studies, we used transwell invasion and migration
assays and growth in soft agar to further characterize the effects of Y15
on the HuH6 cell line. At a concentration of 2.5 μM, there was a
statistically significant difference in cellular invasion and migration fol-
lowing Y15 treatment (Figure W1, A and B). Examining attachment-
independent growth in soft agar, Y15 treatment (2.5 μM) decreased
colony formation from 336 ± 52 to 137 ± 15 (control vs Y15, P ≤
0.05; Figure 5C). To determine whether Y15 caused apoptosis in the
HuH6 hepatoblastoma cells, we used immunoblot analysis for PARP
cleavage products and a caspase-3 activation assay. After a 48-hour treat-
ment with Y15, there was an increase in PARP cleavage products with
increasing Y15 concentrations (Figure 5D). Furthermore, after treat-
ment with 5 μM Y15, there was a statistically significant increase in
activated caspase-3 (Figure 5E ). Since these findings were similar to
those seen with PF, we proceeded with animal studies using Y15 for
FAK inhibition.
Treatment with Y15 Inhibited Growth of
Human Hepatoblastoma Xenografts
To determine the in vivo effect of FAK inhibition upon hepato-
blastoma, we used a nude mouse xenograft model. Human hepato-
blastoma cells, HuH6, were injected subcutaneously into the right
flank and mice were randomized at the time of injection to receive
either saline (vehicle) control (N = 9) or Y15 (N = 10) beginning
the day after cells were injected. Animals were treated twice daily with
intraperitoneal injections of 15 mg/kg Y15. Treatment was discon-
tinued and animals were killed at four weeks, the time point that the
control tumors reached maximal size allowed by protocol. The Y15-
treated animals did not demonstrate any obvious toxicity compared
to controls. Treatment with Y15 resulted in a significant decrease in
HuH6 tumor volume compared to vehicle-treated animals (Figure 6A).
Previous studies showed that Y15 did target FAK phosphorylation
in tumor xenografts [10–12]. Therefore, we wished to determine
whether Y15 treatment resulted in decreased phosphorylation of FAK
in vivo for theHuH6 tumor xenografts. Tumor specimens were homog-
enized and lysates were collected. The tumor protein lysates were anal-
yzed with immunoblot analysis for FAK (Y397) and total FAK. A
representative immunoblot showing a decrease in FAK phosphorylation
in those tumors treated with Y15 compared to those treated with vehicle
was presented in Figure 6B. Densitometry of the blot showed a decrease
in the phosphorylated FAK to total FAK ratio (Figure 6B, top right
graph). Using densitometry evaluation of immunoblots from all of the
in vivo tumor lysates, we determined that Y15 treatment decreased the
pFAK/FAK ratio (Figure 6B, bottom panel) from 0.86 ± 0.10 to 0.36 ±
0.16 (control vs Y15, P = .03) in the protein lysates from the tumor
xenografts. Representative photomicrographs at 20× of immunohisto-
chemical staining for total and phosphorylated FAK of the formalin-
fixed, paraffin-embedded xenograft samples were presented in Figure 6C.
The larger images correspond to black boxes in photomicrographs.
Immunohistochemical staining showed findings similar to immunoblot
analysis; the tumors from the animals treated with Y15 had decreased
FAK Y397 phosphorylation compared to the vehicle-treated tumors
(bottom row). Negative controls were included in each immunohisto-
chemical run (Figure 6C , white inserts).
Discussion
Hepatoblastoma continues to present a therapeutic challenge, and
prognosis remains dismal for patients with advanced and metastatic
disease, highlighting the need for novel treatments. In the current
study, we investigated the role of FAK in hepatoblastoma tumorigen-
esis. Our rationale for studying FAK in hepatoblastoma was three-
fold. First, FAK has been shown to be important in another pediatric
solid tumor, neuroblastoma. In neuroblastoma, FAK has been shown
to regulate cell survival, adhesion, and invasive potential [6,15]. Sec-
ond, FAK expression and phosphorylation have been found in the
adult liver tumor, hepatocellular carcinoma. Chen et al. demonstrated
that FAK expression correlated with tumor stage and vascular invasion
in hepatocellular carcinoma [13]. In addition, other investigators have
shown that in human hepatocellullar carcinoma tumor specimens,
increased FAK mRNA abundance [18] and increased FAK protein
expression [19] was associated with worse disease-free and overall
survival. Finally, there have been other data in hepatoblastoma that
indirectly indicated that FAK may be important in the tumorigenicity
of this tumor. Hsiao recently showed that eight of eight hepatoblas-
toma tumor specimens overexpress Toll-like receptor 4 (TLR4) by
Figure 4. PF treatment of HuH6 cells resulted in cellular apoptosis.
Since PF resulted in decreased cell survival, we examined the
effects of PF on apoptosis in the HuH6 hepatoblastoma cell line.
(A) HuH6 cells were treated for 48 hours with increasing concen-
trations of PF. Apoptosis was measured with a caspase activation
kit. Caspase-3 was significantly activated after treatment with PF.
(B) To further document that the cells were undergoing apoptosis,
HuH6 cells were treated with PF at increasing concentrations for
48 hours, and lysates were examined with immunoblot analysis
for PARP cleavage products. Treatment with PF led to an increase
in cleaved PARP, again, indicating that PF led to apoptosis in the
HuH6 cell line.
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immunohistochemistry and that this overexpression of TLR4 was
absent in eight of eight tumor specimens following chemotherapy.
They also showed that the TLR4 agonist, lipopolysaccharide, inhib-
ited motility and invasion of hepatoblastoma cells in vitro [20]. In
2007, Leaphart and colleagues reported that TLR4 coimmunoprecipi-
tates with FAK and leads to FAK phosphorylation in intestinal endo-
thelial cells [21]. Therefore, there may be potential for FAK to interact
with TLR4 in hepatoblastoma. Previous studies have also demonstrated
that PI3K and protein kinase B (AKT) played a role in hepatoblastoma
cell survival [22,23]. Hartmann and colleagues found that 79% of
human hepatoblastoma tumor specimens examined had strong expres-
sion of phospho-AKT [22]. In addition, inhibition of the PI3K path-
way in vitro resulted in decreased proliferation of hepatoblastoma
tumor cells and cellular apoptosis [22]. Recently, Wagner et al. found
that inhibition of the AKT/mammalian target of rapamycin pathways
with mammalian target of rapamycin inhibitors resulted in a significant
decrease in tumor volume in a murine xenograft model of hepatoblas-
toma [23]. FAK has been shown to interact with the PI3K/AKT axis to
Figure 5. Y15 inhibition of FAK phosphorylation in HuH6 human hepatoblastoma cells. In anticipation of advancing to in vivo experi-
ments, with the knowledge that PF was not formulated for animals, we began investigations with another small molecule FAK inhibitor,
Y15. (A) HuH6 cells were treated for 48 hours with increasing concentrations of Y15 and cell lysates were obtained. Immunoblot analysis
was used to examine FAK Y397 phosphorylation and total FAK in the lysates. Densitometry was performed, and FAK phosphorylation
was reported as a ratio between the density of the Y397 phospho-FAK band to the density of the total FAK band. Increasing concentra-
tions of Y15 resulted in decreased FAK phosphorylation. (B) AlamarBlue assay was used to measure cell viability. HuH6 hepatoblastoma
cells were treated with Y15 at increasing concentrations for 48 hours. Cellular viability was decreased with treatment of 5 μM concen-
tration. (C) Attachment-independent growth in soft agar was employed to further characterize tumor invasiveness. HuH6 cells were
treated with increasing concentrations of Y15, grown in soft agar for 12 days, and colonies were quantified. Colony count was signif-
icantly decreased with Y15 treatment compared to untreated cells. (D) Since Y15 resulted in decreased cell survival, we examined the
effects of Y15 on apoptosis in the HuH6 cells. HuH6 cells were treated with Y15 at increasing concentrations for 48 hours and lysates
were examined with immunoblot analysis for PARP cleavage products. There was an increase in cleaved PARP beginning at the 5 μM
concentration. (E) To further document apoptosis, HuH6 cells were treated for 48 hours with increasing concentrations of Y15.
Apoptosis wasmeasured with a caspase activation kit. Caspase-3 was significantly activated after Y15 treatment, corroborating the PARP
cleavage data and indicating that Y15 treatment resulted in HuH6 cell apoptosis.
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Figure 6. Treatment with Y15 inhibited growth of human hepatoblastoma xenografts. The investigations were advanced to a nude
mouse xenograft model of hepatoblastoma. HuH6 cells were injected subcutaneously into the right flank. At the time of injection, ani-
mals were randomized to receive twice daily intraperitoneal injections of vehicle (N = 9, sterile normal saline, control, 100 μl) or Y15
(N = 10, 30 mg/kg/day, 100 μl). Animals were killed after 28 days treatment and their tumors harvested for study. (A) Tumor volumes were
measured twice weekly with calipers and reported as fold change in tumor volume. In the animals receiving Y15 treatment, there was a
significant decrease in the tumor volumes when compared to control-treated animals. (B) Tumors were homogenized and proteins were
separated on SDS–polyacrylamide gel electrophoresis gels; immunoblot analysis for Y397 and total FAK were performed, with a represen-
tative immunoblot shown. There was a decrease in FAK phosphorylation (Y397) in the animals that received Y15 treatment (top left blot)
that was further demonstrated by densitometry (top right graph). Immunoblots from a number of specimens were analyzed with densi-
tometry. Phosphorylated FAK was expressed as a ratio to total FAK for each blot and normalized to the GAPDH for that blot, allowing for
a comparison to be made between the saline-treated and the Y15-treated tumors. There was a significant decrease in the FAK phosphory-
lation (Y397) in the tumors from the animals treated with Y15 (bottom panel). (C) Representative photomicrographs at 20× of immuno-
histochemical staining of the formalin-fixed, paraffin-embedded HuH6 xenograft samples. The larger images correspond to the black
boxes in photomicrographs. Immunohistochemical staining showed findings similar to immunoblot analysis; the tumors from the animals
treated with Y15 had decreased FAK Y397 phosphorylation compared to the vehicle-treated tumors (bottom row). Negative controls were
performed with each run (white inserts in left panels).
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interrupt apoptotic pathways and increase tumor cell migration in
breast and colorectal cancer, respectively [24,25]. The proven impor-
tance of PI3K/AKT in hepatoblastoma and the known cross talk
between this pathway and FAK again lend credence to the hypothesis
that FAK would be present and important to hepatoblastoma and
support the need to begin to describe its role in this tumor.
In the current study, we found FAK expression in 23 of the 28 tumor
specimens that were examined with immunohistochemistry. In addi-
tion, FAK was phosphorylated in the majority of these 28 hepatoblas-
toma specimens. A stain score was calculated for these specimens and the
median stain score for FAK was 33.7. Although our numbers were too
small to be used to determine prognostic significance and that was not
the goal of the current investigation, on the basis of a previous study in
neuroblastoma using the same stain scoring system [6], the stain scores
for hepatoblastoma appear relevant. In the neuroblastoma study, the
median stain score for FAK was 25, and FAK staining was noted to
correlate with worse disease [6], with stain scores that were well below
those noted in the current study. We also obtained the human hepato-
blastoma cell line, HuH6, and confirmed that FAK was present and
was phosphorylated at the Y397 site. After reviewing the literature, we
determined that the characterization of FAK in hepatoblastoma has
not previously been described.
Previously, researchers have proven that siRNA led to muted FAK
expression with decreased cellular viability, decreased migration, and
increased sensitivity to chemotherapy in lung, pancreatic, and other
cancer cell lines [7,15,26,27]. For example, Han and others demon-
strated a significant decrease in lung cancer cell soft agar colony for-
mation following FAK abrogation with siRNA [7]. Walsh found that
siRNA-induced FAK inhibition had a significant effect upon cellular
adhesion to collagen in the human colon cancer cell line, SW620 [27].
In the current study, we showed through immunoblot analysis that
FAK expression could be abrogated with RNAi in hepatoblastoma cells.
In addition, this focused silencing of FAK resulted in decreased cellular
viability in the HuH6 hepatoblastoma cells. RNAi techniques to inhibit
FAK were employed to minimize potential off-target effects that could
prove a potential critique of small molecule inhibition. These data were
the first step to elucidating the effects of decreasing FAK in hepatoblas-
toma, prompting our investigations with small molecule FAK inhibitors.
Several small molecules have been isolated, which have been shown
to inhibit the activity of FAK, including the compound PF and a sim-
ilar compound PF-562,271. PF interacts with FAK in the adenosine
triphosphate (ATP) binding pocket and blocks the catalytic activity of
FAK [17]. The other compound, PF-562,271, is less selective, in that
it also inhibits PyK2 [28], leading us to choose PF for our investigations
in an attempt to limit potential off-target effects. In previous experi-
ments, PF was shown to decrease adhesion and migration of human
epithelial carcinoma cells [17] and small cell lung cancer cells [29] and
to enhance chemotherapy-induced cytotoxicity and apoptosis inmultiple
human pancreatic cell lines [26]. Wendt et al. proved that inhibiting
FAK with PF decreased invasion and metastatic potential in human
breast cancer cells through blocking the FAK activation of transforming
growth factor β [24]. Similar to previous descriptions, PF effectively in-
hibited FAK phosphorylation in the HuH6 cell line, resulting in de-
creased cellular viability and increased cellular apoptosis. In addition,
other harbingers of increased tumorigenicity such as invasion,migration,
and attachment-independent growth were inhibited with PF-induced
FAK inhibition. The important point to note from this study was that
invasion and migration were inhibited with concentrations of PF that
were below those needed for a significant loss of viability.
PF is suitable for in vitro studies only [17]. Therefore, we chose
another FAK inhibitor, Y15, which has been used for multiple in vivo
studies [10–12]. Y15 is one of only a few small molecule FAK inhib-
itors that may be used in animal studies. Y15 has been shown previ-
ously to both directly inhibit autophosphorylation of FAK at the
Y397 site and decrease total FAK expression [11,12]. Golubovskaya
and others showed that Y15 treatment resulted in dose-dependent
cellular detachment and decreased cellular viability in human breast
cancer cells [10]. In addition, Y15 inhibition of FAK expression in
neuroblastoma led to decreased cellular viability and attachment and
increased apoptosis [12]. With evidence that Y15 caused decreased cell
survival in other cancers and since it could be used in vivo, we chose to
test its effects on human hepatoblastoma cells. Y15 treatment of these
cells did result in diminished FAK phosphorylation. Further, treatment
with Y15 resulted in decreased cellular viability, invasion, migration,
and attachment-independent colony formation. Similar to PF, Y15
treatment also resulted in cellular apoptosis. Finally, as seen with the
PF data, the decrease in migration and invasion seen in the cells
occurred at a concentration of Y15 below that required for decreased
viability. Certainly, the effects upon cellular viability from the small
molecule inhibitors could be an off-target effect upon another cell
survival signaling pathway other than FAK. However, RNAi inhibition
of FAK resulted in similar findings to those of the small molecules,
reducing the possibility of off-target effects.
Because of the effects of FAK inhibition in vitro with both RNAi
and small molecule inhibitors, we advanced our investigations into a
xenograft animal model of hepatoblastoma. Previous studies have
shown that HuH6 cells will reliably form tumor xenografts in a murine
model [24], and this was also true in our study. Further, we found that
animals treated with Y15 had a significant decrease in their tumor
volumes compared to animals treated with vehicle alone. In addition,
there was a decrease in the target (FAK Y397) in the treated tumor
xenografts by immunohistochemistry and a significant decrease in the
pFAK/FAK ratio as detected by immunoblot analysis.
In conclusion, we believe that FAK plays an important role in the
tumorigenicity of hepatoblastoma. Other investigators have been
evaluating the efficacy of other kinase inhibitors in hepatoblastoma.
Recently, the Aurora kinase inhibitor, VX-680, was shown in vitro to
inhibit proliferation of HuH6 cells [30], indicating interest in the use
of kinase inhibitors for this tumor. We believe that we have shown
that FAK inhibition warrants further investigation as a potential ther-
apeutic target in the treatment of hepatoblastoma.
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Figure W1. Y15 treatment of HuH6 cells led to decreased cellular
invasion and migration. (A) HuH6 cells were treated with increas-
ing concentrations of Y15 and allowed to invade through a Matrigel-
coated micropore insert. Invasion was reported as fold change.
Cellular invasion was significantly decreased with Y15 beginning
at the 2.5 μM concentration. (B) HuH6 cells were treated with
increasing concentrations of Y15 and allowed to migrate through
a micropore insert. Migration was reported as fold change in num-
ber of cells migrating through the membrane. Cellular migration
was significantly decreased with Y15 treatment at a concentration
of 1 μM.
